Status:
COMPLETED
Study Evaluating The Coadministration of Begacestat And Donepezil
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborating Sponsors:
Pfizer
Conditions:
Healthy Subjects
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
This study examines the cardiac effects (effects on the heart) of administering donepezil and begacestat together to healthy subjects.
Eligibility Criteria
Inclusion
- Healthy
- Men and women of non-childbearing potential
- Non smoker or smoker of \<10 cigarettes per day and able to refrain from smoking during study
- 18-50 years old
Exclusion
- Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
- Cardiac rhythm abnormalities
- Family history of cardiac risk factors
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00959881
Start Date
August 1 2009
End Date
November 1 2009
Last Update
April 4 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Overland Park, Kansas, United States, 66211